• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A sarcoma hypoxia signature (nanoString (R) assay) validates in the phase III VorteX radiotherapy trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Forker, Laura-Jane
    Bibby, Becky A
    Yang, Lingjian
    Irlam, Joely J
    Valentine, Helen R
    Shenjere, Patrick
    Wylie, James P
    Leahy, Michael G
    Gaunt, P.
    Billingham, L.
    Robinson, M.
    Choudhury, Ananya
    West, Catharine M L
    Show allShow less
    Affiliation
    University of Manchester, Translational Radiobiology, Manchester,
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Purpose or Objective Soft tissue sarcomas (STS) are a rare group of tumours encompassing ~50 malignant, heterogeneous subtypes. Localised disease is managed with surgery ± radiotherapy. Neoadjuvant radiotherapy response is varied and despite high metastatic recurrence rates, there is no definite overall survival benefit from the addition of systemic chemotherapy. Each subtype is very rare; therefore, biomarkers of adverse biological features present across subtypes might be more successful in selecting high-risk patients for clinical trials. Tumour hypoxia is associated with poor radiotherapy response and metastasis. We previously derived a 24-gene STS hypoxia signature that was prognostic in two independent cohorts. The study aims were (1) signature validation in a new whole transcriptome cohort (2) assay development for pretreatment biopsies (3) assay validation. Material and Methods Three cohorts were used (1) VorteX n=203 (2) single centre retrospective n=165 (3) MCRC Biobank n=28. VorteX was a randomised phase III trial comparing radiotherapy volumes in adults with localised extremity STS. Validation cohorts included mainly high-risk patients (85% high-grade). Whole transcriptome RNA-sequencing data (Illumina HiSeq4000) were generated from fresh frozen tumour samples for VorteX. Two targeted assays (Taqman® array cards and nanoString®) were compared in formalin-fixed, paraffin-embedded (FFPE) biopsies. Prognostic validation of the nanoString® assay was performed in FFPE samples from the retrospective and VorteX cohorts. Intra-tumour heterogeneity was assessed in patients (n=10) with multiple biopsies and compared with CAIX expression. Results In the RNA-sequencing VorteX cohort, data were generated for 125/140 patients with available tissue. There was a trend towards poor disease-free survival (DFS) in patients with hypoxic tumours (HR 1.68 95% CI 0.95-2.98 p=0.061). Taqman® array cards and nanoString® demonstrated excellent pass rates and reproducibility. The nanoString® was more sensitive, required lower input and can measure more genes simultaneously. The gene signature showed considerably less intra-tumour heterogeneity than a single marker (figure 1). The nanoString® assay produced a result for 126/127 (99.2%) and 154/159 (96.9%) of patients with sufficient RNA yield and classified 41.3% and 44.8% of samples as hypoxic from the retrospective and VorteX cohorts, respectively. In a univariate analysis patients with hypoxic tumours had worse disease free survival in both cohorts (retrospective HR 2.302 95% CI 1.182-4.486 p=0.0083, VorteX HR 1.687 95% CI 1.013-2.81 p=0.0377) Conclusion A hypoxia signature nanoString® assay with excellent technical performance is prognostic in two independent cohorts of patients with high-grade tumours, including the phase III VorteX radiotherapy trial. The assay could identify high-risk patients for adjuvant chemotherapy trials.
    Citation
    Forker L, Bibby B, Yang L, Irlam J, Valentine H, Shenjere P, et al. OC-0086: A sarcoma hypoxia signature (nanoString® assay) validates in the phase III VorteX radiotherapy trial. Radiotherapy and Oncology . 2020 Nov;152:S39–40.
    Journal
    Radiotherapy and Oncology
    URI
    http://hdl.handle.net/10541/624146
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.